Skip to main content

Table 2 Primary KIT and PDGFRA mutational status in Study 1199

From: Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Mutational status

Study 1199 (N = 230) n (%)

KIT primary mutation

 

 Any

197 (86)

  Exon 9

42 (18)

  Exon 11

143 (62)

  Exon 13

5 (2)

  Exon 17

6 (3)

  Other

1 (<1)

 Wild-type

9 (4)

 Absenta

23 (10)

 Missingb

1 (<1)

PDGFRA primary mutation

 

 Any

18 (8)c

  Exon 10

1 (<1)

  Exon 12

1 (<1)

  Exon 18

5 (2)

  Other

11 (5)c

 Absenta

97 (42)

 Missingb

115 (50)

  1. PDGFRA, platelet-derived growth factor receptor-α
  2. aMutational status was classified as “absent” if no mutations were found but only a subset of the key exons were assessed
  3. bMutational status was classified as “missing” if no assessments were performed
  4. c6 patients (3%) with tumor genotypes classified as "other" were wild-type for PDGFRA mutations status